福泰制药（Vertex Pharmaceuticals）旗下在研药物Povetacicept的加速审批进程正稳步推进，美国食品药品监督管理局（FDA）设定的处方药用户付费法案（PDUFA）目标决定日期为11月30日。该日期标志着监管机构对该药物加速批准申请作出审评结论的关键节点。
福泰制药（Vertex Pharmaceuticals）旗下在研药物Povetacicept的加速审批进程正稳步推进，美国食品药品监督管理局（FDA）设定的处方药用户付费法案（PDUFA）目标决定日期为11月30日。该日期标志着监管机构对该药物加速批准申请作出审评结论的关键节点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.